A head-to-head comparison of plasma biomarkers to detect biologically defined Alzheimer in a memory clinic

Federica Anastasi,Aida Fernández-Lebrero,Nicholas J Ashton,Paula Ortiz-Romero,Javier Torres-Torronteras,Armand González-Escalante,Marta Milà-Alomà,José Contador,Greta Garcia-Escobar,Rosa Maria Manero-Borràs,Irene Navalpotro-Gómez,Aparna Sahajan,Qinyu Hao,Bingqing Zhang,Andreas Jeromin,Nathalie Le Bastard,Alicia Nadal,Tahmine Mousavi,Gwendlyn Kollmorgen,Margherita Carboni,Oriol Grau-Rivera,Henrik Zetterberg,Marta del Campo,Kaj Blennow,Albert Puig-Pijoan,Marc Suárez-Calvet

DOI: https://doi.org/10.1101/2024.10.26.24316176

2024-10-27

Abstract:INTRODUCTION: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. METHODS: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort at Hospital del Mar (Barcelona) were analysed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ status. RESULTS: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting biologically defined AD. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior AUC. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. DISCUSSION: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in distinguishing biologically defined AD in a memory clinic setting.

Neurology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the ability of multiple plasma biomarkers to detect biologically - defined Alzheimer's disease (AD) in a clinical setting. Specifically, the researchers hope to determine which biomarkers are most effective in detecting AD in memory clinics by directly comparing the diagnostic performance of different plasma biomarkers such as p - tau181, p - tau217, p - tau231, total tau protein, and the Aβ42/40 ratio. The goal of the study is to provide a basis for selecting the most appropriate plasma biomarker in clinical practice, thereby improving the early diagnosis rate and accuracy of AD.

### Main research questions:
1. **Compare the diagnostic performance of different plasma biomarkers**: Evaluate the performance of p - tau181, p - tau217, p - tau231, total tau protein, and the Aβ42/40 ratio in detecting AD by analyzing plasma samples from 197 participants.
2. **Determine the best plasma biomarker**: Find out which plasma biomarkers perform best in distinguishing AD patients from non - AD patients, especially which markers have the highest diagnostic specificity and sensitivity.
3. **Verify the correlation between plasma biomarkers and cerebrospinal fluid (CSF) biomarkers**: Evaluate the correlation between plasma biomarkers and the corresponding CSF biomarkers to determine whether plasma markers can be an effective substitute for CSF markers.

### Research background:
- **Importance of plasma biomarkers**: Plasma biomarkers are of great value in the early diagnosis of AD because of their non - invasiveness and easy accessibility.
- **Limitations of existing research**: Although many studies have explored the diagnostic performance of plasma biomarkers, relatively few studies have directly compared multiple biomarkers in a clinical setting.
- **Performance of specific biomarkers**: In particular, the p - tau217 marker has shown high diagnostic performance in many previous studies, so this study pays special attention to the performance of this marker.

### Method overview:
- **Participants**: 197 participants from the BIODEGMAR cohort who were evaluated for cognitive and behavioral symptoms in a memory clinic.
- **Sample collection**: Plasma and cerebrospinal fluid samples were collected simultaneously, and biomarkers were measured using multiple immunoassay methods.
- **Statistical analysis**: The diagnostic performance of each biomarker was evaluated by receiver operating characteristic curve (ROC) analysis, and the area under the curve (AUC), sensitivity, and specificity were calculated.

### Highlights of the results:
- **Superiority of the p - tau217 marker**: Among all the evaluated plasma biomarkers, the p - tau217 marker showed the highest diagnostic performance, with an AUC value of up to 0.97.
- **Correlation with CSF biomarkers**: The p - tau217 marker showed the strongest correlation between plasma and CSF levels, indicating its potential clinical application value.

Through this study, the authors hope to provide reliable evidence for clinicians to select the most effective plasma biomarker to assist in the diagnosis of AD in daily practice.